Alzamend (ALZN) Stock Skyrockets Following Clinical Trial Partnership
Alzamend Neuro, Inc.’s (NASDAQ: ALZN) stock has had a tremendous increase, surging 468.26% to $11.55 on the company’s announcement of a major new clinical trial agreement. This sharp rise in the stock price reflects the market’s enthusiasm for Alzamend’s most recent endeavor. Alzamend Formed Strategic Partnership Alzamend and Massachusetts General Hospital, a renowned clinical education […]